Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989433 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL8485 | 0.77 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| Ammonia Solution, Strong SCHEMBL27469603 | 0.75 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| Hydrochloric Acid SCHEMBL12503316 | 0.75 | KDM4E (0.41) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL51254 | 0.71 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL2186411 | 0.71 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL873444 | 0.71 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL1957441 | 0.71 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL5269898 | 0.71 | GBA1 (0.50) | — | |
| SCHEMBL5152191 | 0.71 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | claimed |
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | claimed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | claimed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | claimed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | claimed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| EP-2970258-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-01-07 | — | — | US | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| US-9163019-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-20 | — | — | US | claimed |
| US-20140303153-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | claimed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | claimed |
| WO-2014140184-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | claimed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | claimed |
| EP-2776418-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-09-17 | — | — | EP | claimed |
| WO-2013068470-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | WO | claimed |
| US-20130116241-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | claimed |
| US-20130116233-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | claimed |
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | disclosed |
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970258-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9163019-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-20 | — | — | US | disclosed |
| US-20140303153-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014140184-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140184-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303153-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | SLC6A2 387/4885SLC6A4 544/4885SLC6A3 413/4885 |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | SLC6A2 1970/4885SLC6A4 1479/4885SLC6A3 1046/4885 |
| US-20130116241-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | SLC6A2 1970/4885SLC6A4 1479/4885SLC6A3 1046/4885 |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | PDE5A, PDE3A, PDE3B | SLC6A2 204/4885SLC6A4 445/4885SLC6A3 259/4885 |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | SLC6A2 387/4885SLC6A4 544/4885SLC6A3 413/4885 |
| US-20130116233-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | SLC6A2 796/4885SLC6A4 1205/4885SLC6A3 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.